Immutep investors sue over alleged SEC violations and misleading statements.

Immutep Limited is facing a class action lawsuit for alleged violations of securities laws. The lawsuit claims that the company made false and misleading statements about its TACTI-004 trial of eftilagimod alfa, despite knowing it would fail to meet primary endpoints for efficacy. Shareholders who purchased IMMP shares during the class period are encouraged to contact the firm regarding possible lead plaintiff appointments. The deadline to join the lawsuit is July 6, 2026.

A class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and several of its senior executives, alleging violations of the Securities Exchange Act of 1934. The lawsuit, captioned Dhaenens v. Immutep Limited, No. 26-cv-03705 (S.D.N.Y.), seeks to represent investors who purchased or acquired Immutep American Depositary Receipts (ADRs) between March 24, 2025, and March 12, 2026, inclusive.

According to the complaint, the defendants allegedly made false and misleading statements regarding the TACTI-004 Phase III clinical trial of eftilagimod alfa (efti), a drug candidate for the treatment of non-small cell lung cancer. The lawsuit claims that the company concealed or misrepresented the trial’s true status and prospects, despite internal data suggesting it would fail to meet its primary efficacy and safety endpoints. The defendants reportedly continued to highlight “strong operational progress” and referenced positive results from earlier trials, such as TACTI-002 and INSIGHT-003, to maintain an optimistic outlook.

On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 trial had recommended discontinuing the study following a planned interim futility analysis. The IDMC concluded that the available data did not support the trial’s continuation. This disclosure led to a sharp decline in Immutep’s stock price, with ADRs falling more than 82% in a single day.

The lawsuit asserts that investors were misled by the defendants’ statements, which allegedly inflated the stock price during the class period. Shareholders who purchased IMMP shares during this timeframe may be eligible to participate in the case and are encouraged to contact legal counsel regarding potential lead plaintiff appointments. The deadline to file a lead plaintiff motion is July 6, 2026.

The Private Securities Litigation Reform Act of 1995 allows investors to seek appointment as lead plaintiff in the case. A lead plaintiff is typically the investor with the greatest financial interest in the relief sought and who is representative of the class. Investors who do not serve as lead plaintiff may still be eligible to share in any potential recovery.

The case is being pursued by multiple law firms, including Robbins Geller Rudman & Dowd LLP, The Schall Law Firm, and The Gross Law Firm, among others (multiple law firms pursuing the case)(The Schall Law Firm)(The Gross Law Firm). These firms have extensive experience in securities litigation and have previously secured significant recoveries for investors in similar cases. Investors are advised to consult with qualified legal counsel for further information.